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Abstract 
Malaria is a life-threatening mosquito-borne disease caused by parasites of the genus 
Plasmodium, with about 200 million new cases reported each year. In rodent models of malaria, 
a variety of immune proteins called cytokines have been noted to either promote or suppress 
protective immunity. While the cytokine interleukin-3 (IL-3) clearly promotes host defense 
against some intestinal nematode parasites, few studies have reported a similar function for IL-3 
in the pathophysiology of malaria. In this study, we investigated the role of IL-3 in a mouse 
model of cerebral malaria caused by Plasmodium berghei ANKA. We infected wild-type (WT) 
and IL-3 deficient (IL-3 KO) mice with P. berghei ANKA and characterized parameters 
indicative of a protective host response to infection. We found that male IL-3 KO mice generally 
survived longer than corresponding WT mice, although no differences between blood 
parasitemia or hematocrit levels were observed between the two genotypes. In addition, male IL-
3 KO mice had an increased splenomegaly, and at day 6 p.i. showed less vascular damage in the 
brain than did corresponding infected WT mice. These findings suggest that IL-3 plays a role in 
suppressing protective immunity in a mouse model of cerebral malaria.  
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Introduction 
Overview of Malaria 
     Malaria is a deadly infectious disease with an expansive prevalence worldwide. Over 40% of 
the world’s population lives in areas where malaria is endemic, and annually, there are 300 to 
500 million new cases of malaria reported, according to the National Institute of Allergy and 
Infectious Disease (“Understanding Malaria”, 2007). The World Health Organization reported 
that in 2015, 438,000 deaths were caused by malaria, and while there has been a 48% decline in 
mortality rate since 2000, the number still remains elevated (World Malaria Report, 2015).  
Malaria prevalence is highest in tropical and subtropical areas near the equator, including 
countries in Asia, Africa, Central and South America. Many of these areas do not have the 
infrastructure, preventative care, or treatment options necessary to combat malaria. The high 
prevalence in these regions is primarily due to the malarial vector, the female Anopheles 
mosquito, which thrives well in moist, warm regions.  
Plasmodium Life Cycle  
     Malarial infections are caused by the eukaryotic protozoan Plasmodium. Although there are 
over 100 different species of Plasmodium, only four species of Plasmodium commonly infect 
humans: P. falciparum, P. vivax, P. malariae, and P. ovale. All four of these species cause 
slightly different clinical manifestations and infect at different rates. Additionally, a fifth species 
of Plasmodium previously thought to only infect monkeys, P. knowlesi, has been attributed to 
human cases of malaria in South-East Asia (Singh et al., 2004).  
     Although the clinical manifestation of various Plasmodium species may differ, the life cycle 
of all Plasmodium species is similar (Miller et al., 2002). Transmission of malaria occurs when 
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the infected female Anopheles mosquito takes a blood meal from a vertebrate host. As the 
mosquito takes blood, the infectious parasites in the mosquito saliva are deposited in the form of 
highly motile sporozoites. Sporozoites are 10-15 micrometers in length, spindle shaped, and 
express various surface proteins, including circumsporoite protein, which aid in the binding and 
attack of liver cells. Sporozoites travel through the bloodstream to the parenchymal cells of the 
liver, where expansion and asexual development into merozoites occurs. This process takes 
approximately two weeks. Once capacity is reached within the liver cells, they rupture, releasing 
mature merozoites into the bloodstream thus beginning the erythrocyte cycle or blood-stage 
cycle. Circulating merozoites infect red blood cells (RBCs) by using merozoite surface proteins 
to attach and enter RBCs. Inside the RBCs, the merozoites transform into trophozoites, followed 
by asexual division into a schizont, which contains multiple merozoites. Within the RBCs, 
parasites feed upon the hemoglobin, and release a pigment called hemazoin, an insoluble 
crystalline form of heme. RBCs ultimately rupture and release mature merozoites into the 
bloodstream where they infect other RBCs exponentially. Some merozoites form male and 
female gametocytes within RBCs. When the female Anopheles mosquito takes its next blood 
meal, she will uptake the gametocytes in the blood and the sporogonic cycle will commence 
(Figure 1; Michalakis and François, 2009) . The sporogonic cycle is a 10-18 day period during 
which the gametocytes fuse to form a zygote in the intestine of the mosquito. Once the zygote 
matures into a sporozoite, the parasite will move from the intestine to the salivary glands of the 
female Anopheles mosquito. The next blood meal taken from a human host will transmit the 
sporozoites and the cycle of disease will occur once again.  
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Figure 1. Plasmodium berghei life cycle (Michalakis and François, 2009) 
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Clinical Disease 
The type and severity of clinical symptoms in humans vary depending on the Plasmodium 
strain causing the infection. The two most common parasites in humans are P. falciparum and P. 
vivax, with P. falciparum being the most deadly. If left untreated, infection with P. falciparum 
can cause serious illness, often resulting in death. Almost all clinical symptoms for those infected 
with Plasmodium, including anemia, are a direct result of ruptured RBCs during infection. As 
RBCs rupture, the release of pyrogenic compounds into the blood causes high, uncontrolled 
fevers. Further potential symptoms include headache, vomiting, chills, diarrhea, and muscle pain, 
which become progressively worse as the infection spreads (“Understanding Malaria”, 2007). 
Cerebral malaria is the most consequential neurological manifestation of severe malaria and is 
associated with high mortality. Cerebral malaria occurs when there is significant sequestration of 
parasitized RBC (pRBCs) in the brain microvasculature, causing minimal or no blood flow 
through the brain tissue. Adherence of the pRBCs to the endothelial cells causes damage to the 
endothelial cells and surrounding tissue, disrupting blood flow through the microvasculature. 
This creates a state of hypoxia, which along with compounding inflammation, causes extensive 
neurological damage (Hearn et al., 2000). In addition to the brain, parasite sequestration during 
human malaria infection has been observed in the lungs, skin, gastrointestinal tract, spleen, and 
kidneys. Cytoadhesion of pRBCs in these regions can cause vascular occlusion, chronic 
inflammation, and ultimately organ failure (Halder et al., 2007).  
     Although drug resistant strains of Plasmodium are becoming more common, prevention and 
treatment of malaria has rapidly evolved over the past decade. Effective methods to prevent 
malaria infection include wearing long-sleeves pants to avoid mosquito bites, using mosquito 
nets while sleeping, and other methods of vector control designed to reduce the number of 
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mosquitoes. These methods include indoor residual spraying with insecticides and source 
reduction (larval control) (Pluess et al., 2010). Anti-malarial drugs are also available to those 
traveling to high-risk countries and should be taken before, during, and after travel. Treatment of 
active infections is based heavily on numerous antimalarial drugs, most of which target blood 
stage parasites. Major drugs commonly used to treat malaria include chloroquine, atovaquone, 
artemether, mefloquine, quinine, quinidine, doxycycline and clindamycin. Arteminisin-based 
combination treatment (ACTs) has become the first line of malarial treatment, as it is able to 
effectively target pathogenic asexual blood stages, as well as the transmissible sexual stages of 
the Plasmodium parasite (Eastman et al., 2009). The potent, short half-life of Artemisinin, in 
combination with longer lasting anti-malarial drugs, has provided an increase in treatment 
success rates.  
Mouse Models of Malaria 
     Murine models have long been used in an attempt to understand the pathophysiology of 
countless diseases and to reveal possible treatments that may be effective in human patients. 
Mouse models of malaria infection have greatly contributed to our understanding of the basic 
biology of the parasite, host immune responses, and pathogenesis. At any one time, only a few 
clinical trials with human patients can be conducted to determine the effectiveness of a specific 
new treatment due to population, time, and cost restrictions. Mouse models of malaria infection 
are effective means to study malaria infection for a number of reasons. Mice are relatively 
inexpensive to maintain and comprehensive experiments are possible given that mice have large 
litters and short gestation periods.  Additionally, the mouse genome, although approximately 
14% smaller than the human genome, contains many highly conserved genes and linear 
organization on the chromosomes (Chinwalla et al., 2002). These similarities in the genome 
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make mice a good model organism for studying human disease. While mouse models of malaria 
infection may not be identical to what occurs in humans, both in vitro and in vivo studies provide 
insight into the pathogenesis of Plasmodium in humans. Mouse models are thus seemingly 
limitless when compared to the population size and cost of human trials.  
     Numerous Plasmodium species induce malaria infection in mice, but they vary in lethality 
and immunopathology. Non-lethal Plasmodium strains used to infect mice include P. chabaudi 
chabaudi, P. chabaudi adami, P. yoelii 17XNL, and P. vinckei petteri (Li et al., 2001). 
Importantly, non-lethal strains provide the ability to study chronic infection. Furthermore, 
because mice are able to overcome the infection with these strains, a secondary challenge can be 
performed to better characterize host adaptive immune responses. Common lethal strains of 
mouse malaria that are available include P. berghei ANKA, P. berghei NK65, P. yoelii 17XL 
and P. vinckei vinckei. Death in mice is often caused by severe anemia (Li et al., 2001) and/or 
cerebral malaria (Bagot et al., 2002). Mice can be experimentally infected by using mosquitos or 
through injection of pRBCs into the intraperitoneal cavity. However, most investigators infect 
mice by injecting pRBCs as it is the erythrocytic stage of the life cycle that is primarily 
responsible for most clinical manifestations of disease (Haldar et al., 2007).  
     Cerebral malaria is the most consequential neurological manifestation of severe malaria in 
humans. The most appropriate model to study this aspect of infection is the use of mice infected 
with P. berghei ANKA. In P. berghei ANKA-infected mice, cerebral malaria is the main cause of 
death in susceptible mouse strains. C57BL/6 mice are highly susceptibility to the development of 
cerebral malaria, with 60 to 100% of mice succumbing to infection (Bagot et al., 2002). 
Pathology is mainly due to recruitment and activation of immune cells resulting in tissue damage 
in the brain. Monocytes are sequestered and adhere to the endothelial cells of the brain 
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microvasculature, damaging the cells (Li et al., 2001). Hemorrhaging is caused in part by the 
massive recruitment of CD8+ T cells expressing perforin, a protein that lyses endothelial cells by 
disrupting their plasma membrane (Nitcheu et al., 2003). Additionally, both CD4+ and CD8+ T 
cells secrete a variety of mediators, promoting parasite accumulation within the brain (Amante et 
al., 2010). Mice suffering from cerebral malaria show a number of phenotypic changes. Visual 
indicators of disease severity begin with ruffled fur and slowed movement. During the course of 
disease, mice show signs of ataxia, hyperventilation, convulsions, deviation of the head, 
paralysis, a decrease in body temperature, and coma (Bagot et al., 2002).  
     Cerebral malaria has been studied almost exclusively using the C57BL/6 mice infected with 
P. berghi ANKA (Porcherie et al., 2011). Although these infected mice represent a good model 
of human cerebral malaria, there are distinct histopathological differences evident between 
humans and mice.  In the C57BL/6 murine model, sequestration of leukocytes in the 
microvasculature of the cerebrum, rather than pRBCs, is observed. In addition, significantly 
higher levels of inflammation have been noted in the murine model when compared to the 
pathophysiology in humans (White et al., 2010). While mouse models do not always replicate 
human disease exactly, there are significant similarities in the pathogenesis of infection to justify 
continued work with mouse models of cerebral malaria. For example, studies in humans have 
shown that monocytes coexist with infected P. falciparum-infected erythrocytes in the brain, 
which is similar to what occurs in mice infected with P. berghei ANKA (Porta et al., 1993). 
Interleukin-3 and Malaria  
     Interleukin-3 (IL-3) is a cytokine that is primarily produced by activated T cells; however, 
other cell types have been shown to produce IL-3 such as mast cells (Wodnar-Filipowicz et al., 
1989), basophils (Schroeder et al., 2009), endothelial cells (Dentelli et al., 2011), and neurons 
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and astrocytes in the brain (Konishi et al., 1994). IL-3 is well documented at promoting the in 
vitro differentiation and proliferation of murine hematopoietic progenitor cells as well as survival 
and activation of mature myeloid cells, including mast cells, basophils, dendritic cells, 
neutrophils, eosinophils, macrophages, and RBCs (Schrader et al., 1988). In fact, in vitro culture 
of mouse bone marrow cells with IL-3 is a standard way to generate large numbers of mast cells 
and basophils for further study. IL-3 also affects cellular function. For example, IL-3 has been 
reported to enhance macrophage activation (Frendl et al., 1990), promote the secretory ability of 
eosinophils (Rothenberg et al., 1986), stimulate endothelial cell growth and activation (Dentelli 
et al., 1999), and enhance dendritic cell function (Lutz, 2004). 
     Despite the activities attributed to IL-3, mice lacking the IL-3 gene display no defects in 
hematopoiesis (Mach et al., 1998), and have normal numbers of basophils and mast cells (Lantz 
et al., 1998). These findings and the fact that IL-3 levels in blood or tissues are low or 
undetectable in normal mice, suggest that IL-3 is not involved in hematopoietic cell 
development. On the other hand, experiments with IL-3 gene-deficient (knockout [KO]) mice 
revealed either a suppressive or stimulatory role for IL-3 during certain disease conditions. For 
example, it has been shown that IL-3 KO mice have impaired T cell-dependent contact 
hypersensitivity responses to haptens (Mach et al., 1998), have increased accumulation of 
eosinophils during ragweed-induced allergic peritonitits (Neel et al., 2004), and mount 
attenuated mast cell and basophil response to gastrointestinal nematode infection that results in 
compromised worm expulsion (Lantz et al., 1998). More recently, it has been reported that 
innate response activator B cells produce IL-3, IL-3 deficiency protects mice against sepsis, and 
elevated levels of IL-3 correlate with increased mortality in human septic patients (Weber et al., 
2015).  
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     While these studies have clearly shown that IL-3 production can influence the outcome of 
host immune response, there are but a limited number of reports suggesting a similar role of IL-3 
in the pathophysiology of malaria infections. An increase in IL-3 serum levels was detected in P. 
chabaudi infected mice preceding and around the time of peak parasitemia (Helmby et al., 
1998). Grau et al. has shown that treatment of P. berghei-infected CBA mice with anti-IL-3 and 
anti-GM-CSF antibodies prevents development of cerebral malaria and prolongs survival, 
possibly by preventing increases in TNF-α (1988). It was also demonstrated that IL-3 may 
increase adhesion of parasitized erythrocytes to endothelial cells, a phenomenon associated with 
the pathophysiology of severe malaria (Carlson et al., 1990). IL-3-dependent basophil numbers 
have been observed to increase in malaria-infected mice, but the ability of these cells and their 
cytokines to influence infection remains to be determined (Helmby et al.,1998). More recently, 
polymorphism of the IL-3 gene has been associated with risk of recurrent malaria attacks (Meyer 
et al., 2011). 
     Our laboratory has recently reported that IL-3 plays a critical role in suppressing protective 
immunity to blood-stage malaria infection (Auclair et al., 2014). These studies were conducted 
with IL-3 KO mice infected with P. berghei NK65, a lethal strain of Plasmodium that does not 
induce cerebral malaria. It was shown that male IL-3 KO mice, but not female mice, were more 
resistant to infection than wild-type (WT) mice, as evidenced by lower peak parasitemia and 
prolonged survival. Both male and female IL-3 KO mice had increased splenomegaly and were 
more anemic than corresponding WT mice. Plasma levels of cytokines IFN-γ and CXCL9 were 
found to be significantly reduced in IL-3 KO mice during early stages of infection (Auclair et al., 
2014). Overall, these results indicate that IL-3 suppresses protective immune responses to P. 
berghei NK65 and that it is involved in inhibiting the development of splenomegaly and anemia. 
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     A limited number of reports have also indicated that IL-3 can play a substantial role within 
the brain and the central nervous system as a whole. In vitro and in vivo studies have shown that 
IL-3 is a neurotropic factor for murine central cholinergic neurons, and that specific neurons, 
such as the hippocampal neurons, produce IL-3 in situ (Konishi et al. 1994). Further research 
using a strain of IL-3 transgenic mice, which over express IL-3, resulted in motor neuron disease 
(Chavany et al., 1998). In this study, degeneration of axonal, dendritic, and pyramidal cells in the 
hippocampus and spinal cord were observed. This degeneration of motor neurons in both the 
brain and spinal cord led to forms of paralysis, and numerous neurological damages. The ability 
of IL-3 to influence brain function under some circumstances suggests a potential role for IL-3 in 
the development of mouse cerebral malaria caused by Plasmodium parasites such as P. berghei 
ANKA.  
Project Goals  
     Recently, our laboratory demonstrated that IL-3 KO BALB/c mice have increased resistance 
to blood stage P. berghei NK65 malaria infection (Auclair et al., 2014). Thus, it can be 
concluded that the production of IL-3 may negatively affect resistance to a malaria infection with 
P. berghei NK65. In addition, an overexpression of IL-3 has been shown to cause numerous 
neurological damages, promoting the degradation of neurons (Chavany et al., 1998). These two 
studies, in conjunction with the known influence of IL-3 on brain formation and function, 
indicate that IL-3 could play a significant role in the development of cerebral malaria. Certain 
strains of mice have been shown to be more susceptible to the development of cerebral malaria 
during a P. berghei ANKA infection, but the extent to which IL-3 production influences the 
pathogenesis of cerebral malaria is unknown. This project focused on addressing two specific 
aims outlined below.  
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Aim 1: Establishment of a model of cerebral malaria using P. berghei ANKA-infected 
C57BL/10 mice. 
     Most murine studies of cerebral malaria in utilize C57BL/6 mice. However, C57BL/6 IL-3 
KO mice are not readily available to examine the effects of IL-3 in this model. The related 
mouse strain C57BL/10 has been shown to develop cerebral malaria (Bagot et al., 2002) and 
recently, C57BL/10 IL-3 KO mice became commercially available. Therefore, we established a 
colony of WT and C57BL/10 IL-3 KO mice in our laboratory and initially characterized the 
disease symptoms, which develop in WT C57BL/10 infected with P. berghei ANKA. Because 
the techniques required to induce and monitor the outcome of cerebral malaria in our laboratory 
had not been established, this is a necessary first step. To begin, WT C57BL/10 mice between 8-
12 weeks of age were injected intraperitoneally with 105-106 P. berghei ANKA pRBCs to 
determine the correct dosage of pRBCs to induce mortality 6-10 days post-infection (p.i.). We 
also characterized and quantitated the development of major disease symptoms such as deviation 
of the head, paralysis, ataxia, and decrease in body temperature. Finally, we used infected WT 
C57BL/10 to establish techniques necessary to histologically evaluate the extent of infection in 
the brain. 
Aim 2: Assess the extent to which IL-3 influences the course and outcome of the P. berghei 
ANKA-induced disease. 
     To assess the extent IL-3 influences P. beghei ANKA-induced disease, 8-12 week old 
C57BL/10 WT and IL-3 KO male and female mice were infected intraperitoneally with 106 P. 
berghei ANKA pRBCs. Mortality studies were performed to determine if WT and IL-3 KO mice 
differ in their response to infection. All experiments were performed with 5 to 15 mice per 
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genotype, and all mice will be visually monitored daily until they succumb to the lethal infection. 
Additional groups of 8-12 week WT and KO male and female C57BL/10 mice (n = 5-7 per 
group) were also infected intraperitoneally with 106 P. berghei ANKA pRBCs. These animals 
were monitored and sacrificed prior to death in order to evaluate the influence of IL-3 on a 
number of disease indicators, such as the percentage of pRBCs present in peripheral blood, the 
extent of anemia, body weight, spleen weight, and histological changes in the brain.  
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Materials and Methods 
Mice  
Male and female C57BL/10 WT and IL-3-deficient mice (purchased from the Jackson 
Laboratory, Bar Harbor, ME) were bred in the Department of Biology at James Madison 
University. C57BL/10 WT mice were used as controls for the C57BL/10 IL-3 KO mice. For all 
procedures, age- and sex- matched mice between 8 and 12 weeks of age at the beginning of the 
experiment were used. All mice were housed in a positive-pressure, individually-ventilated 
caging system (Allentown Inc., Allentown, NJ) in the Department of Biology and provided food 
and water at all times. A 14-h/10-h light/dark cycle was set for the vivarium murine rooms, and 
all mice were maintained in accordance with James Madison University’s Institutional Animal 
Care and Use Committee (IACUC) guidelines. 
Plasmodium berghei ANKA Parasites and Infection  
Cryopreserved P. berghi ANKA (MRA-311, ATCC) pRBCs were obtained from the 
American Type Culture Collection (ATTC). Parasites were propagated through mice and after 
one week of infection, infected blood was collected and stored in liquid nitrogen.  P. berghi 
ANKA used for experimental infections was only used if under four serial blood passages 
through mice. Prior to the experimental infection, cryopreserved P. berghi ANKA was passaged 
once through a C57BL/10 WT mouse. Experimental mice were then injected intraperitoneally 
(i.p.) with 106 P. berghi ANKA pRBCs.  
Clinical Assessment of Infection 
     Clinical symptoms of cerebral malaria monitored over time included ruffled fur, ataxia, 
hyperventilation, convulsions, paralysis, deviation of the head, decrease in body temperature, and 
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coma (Hearn et al, 2000). Severity of induced cerebral malaria was monitored and quantified on 
a numeric scale; values ranged from 1 to 5. Numeric values representative of clinical symptoms 
are as follows: (1) no deviations from normal behavior or movement, (2) slight decrease in 
amount and speed of movement, (3) slowed movement, slight head tilt, ruffled fur, (4) lethargic 
movement, evident head tilt, ruffled fur, possible paralysis of extremities, possible convulsions 
and (5) no movement, total paralysis, labored breathing, ruffled fur. All infected mice were 
individually monitored daily for 5 minutes beginning day 1 p.i. for changes in clinical symptoms. 
Blood was collected from anesthetized mice (see below) via cardiac puncture into a 1 mL 
heparinized needle and then was used to evaluate parasitemia and anemia. Parasitemia was 
quantified using Giemsa-stained blood smears via light microscopy in which a minimum of 500 
RBCs were evaluated. Evaluation of anemia was performed by examining hematocrits. Spleens 
were harvested at specific time points post-infection (p.i) and weighed. Splenic index was 
calculated for each mouse using spleen weight (g)/body weight (g) x 1000. All infected mice 
were clinically monitored daily. 
Histological Evaluation of Brain Pathology 
     To histologically assess the extent of cerebral malaria in P. berghi ANKA infected mice, 
perfusions were performed to fix the brain prior to removal. Infected mice were anesthetized 
using the inhalant isoflurane and placed in a supine position. Skin covering the chest cavity was 
removed and a cardiac puncture was performed to remove circulating blood from the system. 
After opening the chest cavity of the mouse, 10 mL of 1% phosphate buffered saline rinse 
followed by 10 mL of 4% paraformaldehyde was injected through the apex of the heart to rinse 
and perfuse, respectively. Brain tissue was removed and placed in 4% paraformaldehyde at 4˚C. 
Paraffin sectioning and staining was performed by Histo-Scientific Research Laboratories, 
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Mount Jackson, VA. Briefly, paraffin-embedded coronal brain sections were cut at 5 micron 
thickness from the forebrain to the hindbrain and stained with hematoxylin and eosin (H&E). 
Histological sections were examined under 100X magnification using standard microscopy 
procedures. To assess neurological pathology, we quantified the extent of damage to brain blood 
vessels and the areas in the brain, which showed evidence of parenchymal hemorrhaging. 
Vessels that were counted only included those of minimum size. These included cross sections of 
vessels with a minimum diameter of 0.05 mm, and transverse sections of vessels 0.1 mm in 
length or 0.25 mm wide and over 0.75 mm in length. Damaged vessels were defined as those 
having more than 25% of their endothelial cells separated from the vessel wall. Parenchymal 
hemorrhaging was defined as those areas of brain tissue containing greater than 5 RBCs at one 
site. The number of parenchymal hemorrhages was standardized by dividing the total number of 
sites containing hemorrhaging by the total area of the brain section. The area was calculated 
using Image J software (National Institute of Health; Bethesda, MD). 
Statistical Analysis  
     Data are presented as the means + standard error of the mean. To determine statistical 
significance, an unpaired t-test was used to compare one variable between two groups. Survival 
curves were analyzed for statistical significance using the log-rank (Mantel Cox) test. A 
significance level of 0.05, 0.01, and 0.001 was used for all comparisons. All statistical analyses 
were conducted using GraphPad Prism software, version 5.02 (GraphPad Software, La Jolla, 
CA).  
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Results 
Establishment of a cerebral malaria model using P. berghei ANKA-infected C57BL/10 
mice.  
One of the aims of this project was to establish a model of cerebral malaria in the laboratory 
using C57BL/10 mice. P. berghei ANKA is a lethal Plasmodium parasite that will ultimately 
cause death in most strains of laboratory mice, including C57BL/10, approximately 6-10 days 
post-infection (p.i.). We therefore performed a number of pilot experiments in the laboratory in 
order to become efficient with techniques required by this model. We were successful in this 
goal and routinely were able to infect C57BL/10 mice and observe those symptoms characteristic 
of the disease (Figure 2). We found that most disease symptoms develop late in infection, 
typically within 24-36 hours prior to death. Signs of infection observed included signs like ruffed 
fur, lethargic movement, convulsions, and ultimately paralysis (Figure 2A and 2B). 
Mice that do not succumb to the infection through the development of cerebral malaria die of 
anemia caused by hyperparasitemia (Bagot et al., 2002).  As the Plasmodium parasite spreads 
systemically, a larger number of RBCs will become infected (Figure 2C). These infected RBCs 
will ultimately rupture, leading to an increase in anemia.  
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Figure 2. Representative images from uninfected and infected mice. Representative images of 
(A) an uninfected and (B) P. berghei ANKA-infected C57BL/10 mouse day 6 p.i., and (C) 
peripheral blood from a day 6 p.i. P. berghei ANKA-infected C57BL/10 mouse (arrows indicate 
pRBCs). Please note in figure B that the mouse is showing ruffed fur and a hunched posture. 
B 
C 
A 
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Mortality rates of P. berghei ANKA-infected male and female IL-3 KO and WT mice.  
To determine if IL-3 influences the survival of infected mice, we first infected male 
C57BL/10 WT and IL-3 KO mice with 106 P. berghei ANKA pRBCs and monitored daily the 
length of time for mice to succumb to infection (Figure 3A). Of the three experiments, only one 
depicted a statistically significant difference between IL-3 KO mice and WT mice (P=0.0002). 
In this experiment, male WT mice began dying day 6 p.i. and all died by day 10 p.i., while most 
male IL-3 KO mice died between days 9 and 16 p.i. Although there was no statistical difference 
between the genotypes in the other two experiments, the data suggests a similar trend with IL-3 
KO mice living slightly longer than WT mice (Figure 3B and data not shown). We also 
evaluated the effect of IL-3 on survival in female mice (n = 5-10 per group) infected with 106 P. 
berghei ANKA pRBCs. However, we saw no statistical difference between female WT and IL-3 
KO mice, with both genotypes dying between 7 and 10 days p.i. (Figure 3C-D). In all studies 
with infected male and female mice, animals exhibited slightly lethargic movement 
approximately 36 hours before death, and major clinical symptoms such as paralysis, head tilt, 
convulsions, and coma developed within 24 hours prior to death.  
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Figure 3. Survival rate of P. berghei ANKA-infected male (A, B) and female mice (C, D) WT 
and IL-3 KO mice (n = 5-15 mice per group). Mice were infected with 106 P. berghei ANKA 
pRBCS and visually monitored until they succumbed to infection.  
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Development of splenomegaly in P. berghei ANKA-infected male IL-3 KO and WT mice.  
One of the major clinical outcomes of malaria infection in mice and humans is enlargement 
of the spleen, or splenomegaly. The spleen, serving as a vital component of the lymphatic 
system, assists the mouse in fighting and controlling blood-borne infections. Plasmodium 
infections cause an enlargement of the spleen, as the spleen responds to infection with an 
increase in immune cell proliferation. Antigens present in the splenic white pulp, in combination 
with damaged RBC destruction in the splenic red pulp, account for spleen enlargement during 
infection (Chotivanich et al, 2002). IL-3 has previously been noted to influence the development 
of splenomegaly in mice infected with P. berghei NK65 (Auclair et al., 2014). We therefore 
wanted to determine if a similar effect was evident in C57BL/10 mice infected with P. berghei 
ANKA. For these experiments, we infected male WT and IL-3 KO mice (n = 5-6 mice per 
group) with 106 P. berghei ANKA pRBCs and sacrificed animals at day 7 p.i. to evaluate 
splenomegaly. 
We found that both genotypes of infected mice had a statically significant increase in their 
splenic index as compared to corresponding uninfected control mice (Figure 4). Importantly, we 
found that infected IL-3 KO mice had a statistically greater increase in their splenic index as 
compared to similarly infected WT mice (Figure 4). In fact, IL-3 KO mice experienced 
approximately a 70% greater increase in spleen size compared to infected WT mice. Similar 
results were obtained in one separate experiment in which infected WT and IL-3 KO mice were 
sacrificed at day 6 p.i. (data not shown). 
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Figure 4. Splenic index of uninfected and P. berghei ANKA-infected male WT and IL-3 KO 
mice. Spleen weights of infected mice were determined on day 7 p.i. The splenic index was 
determined as the ratio of spleen weight to body weight. All data are presented as means + SEM 
from 5 to 6 mice per group analyzed individually. P < 0.01 (**) and P < 0.05 (*) versus 
corresponding values for uninfected mice or (as indicated by the square brackets) versus 
corresponding values for mice of the other genotype. Similar results were obtained in one 
additional experiment. 
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Parasitemia of P. berghei ANKA-infected male IL-3 KO and WT mice.  
The Plasmodium parasite utilizes RBCs to propagate, as the hemoglobin found in RBCs 
serves as the nutrient source for asexual reproduction. Upon completion of replication, the 
Plasmodium parasite will cause the RBC to rupture, allowing for the exponential expansion of 
the Plasmodium infection to occur (Michalakis and François, 2009). Measurement of parasitemia 
levels serves as a good indication of disease severity. To evaluate the influence of IL-3 on the 
parasitemia level of circulating blood, WT and IL-3 KO mice (n = 6 mice per group) were 
infected with 106 P. berghei ANKA pRBCs and sacrificed on day 6 p.i. Blood was collected 
prior to sacrifice through a retro-orbital bleed of the peri-orbital sinus. Parasitemia was 
calculated using Giemsa stained blood smears. Parasitemia levels for WT and IL-3 KO P. 
berghei ANKA-infection mice at day 6 p.i. were not statistically different at day 6 p.i. as both 
genotypes had a parasitemia level between 9% and 11% (Figure 5).  
Anemia of P. berghei ANKA-infected male IL-3 KO and WT mice.  
Numerous Plasmodium strains have been noted to induce anemia. The Plasmodium parasite 
utilizes the hemoglobin found in RBCs as a nutrient source, and after replication has occurred, 
causes the RBC to rupture. Anemia is the result of both RBC lysis as well as parasite-induced 
immunosuppression of erythropoiesis. To determine the role of IL-3 on anemia levels of infected 
mice, hematocrit levels in P. berghei ANKA-infected male IL-3 KO and WT mice (n = 5-6 mice 
per group) were measured in two separate experiments at day 6 p.i. and day 7 p.i. Measurements 
taken at day 6 and 7 p.i. are the same mice depicted in Figures 5 and 4, respectively.  We found 
that infected WT and IL-3 KO mice at days 6 or 7 p.i. depicted no statistical difference in 
hematocrit levels (Figure 6). Furthermore, we saw no evidence of anemia in either infected  
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Figure 5. Percent parasitemia of P. berghei-ANKA infected male WT and IL-3 KO mice at day 
6 p.i. Giemsa stained blood smears were used to calculate the percent parasitemia. All data are 
presented as means + SEM from 6 mice per group analyzed individually.  
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Figure 6. Hematocrit values of uninfected and P. berghei ANKA-infected male WT and IL-3 
KO mice. Hematocrits of infected mice were determined in two separate experiments in which 
mice were sacrificed on day 6 or day 7 p.i. All data are presented as means + SEM from 5 to 6 
mice per group analyzed individually.  
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genotype as compared to corresponding uninfected control mice. All mice had a hematocrit level 
between 38 and 44%. 
Brain histopathology of P. berghei ANKA-infected male IL-3 KO and WT mice.  
Cerebral malaria is a common cause of mortality for both humans and mice infected with 
malaria. The P. berghei ANKA strain is known to induce neurological complications in mice due 
to sequestration of pRBCs in brain microvasculature. This leads to endothelial cell damage and 
subsequent hemorrhaging. In order to initially characterize histological changes in the brain 
microvasculature in our specific model system, we first performed a number of pilot experiments 
using uninfected and P. berghei ANKA-infected mice. We found that coronal brain sections 
from uninfected mice had typical vasculature morphology (Figure 7A), whereas vessels from 
infected mice had significant endothelial cell separation, and leukocyte and pRBC accumulation 
(Figure 7B). In addition, we noted areas of the parenchymal hemorrhaging present in the brain 
tissue (Figure 7C).  
To determine the extent IL-3 influences histopathology within the brain microvasculature 
during infection, male C57BL/10 WT and IL-3 KO mice (n = 5 - 6 mice per group) were 
infected with 106 P. berghei ANKA pRBCs. At day 6 p.i., mice were sacrificed and paraffin 
embedded coronal brain slices were generated and stained with hematoxylin and eosin (H&E). 
Brain histological analysis included calculating the percentage of vessels with evidence of 
endothelial cell damage and/or cellular sequestration, and determining the number of sites per 
section with evidence of parenchymal hemorrhaging. We found that infection of both WT and 
IL-3 KO mice with P. berghei ANKA induced significant increases in the number of damaged 
vessels (Figure 8) and in the extent of parenchymal hemorrhaging as compared to  
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Figure 7. Cerebral malaria brain histology. Representative images of (A) an undamaged, 
transverse brain blood vessel section, (B) a damaged cross sectional section of a brain blood 
vessel containing endothelial cell separation and leukocyte accumulation, and (C) parenchymal 
hemorrhaging present in brain tissue.  All coronal brain sections of the cortex were stained with 
H&E and were viewed at 400x magnification by standard microscopy.  
 
 
 
 
A 
C 
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Figure 8. Percentage of damaged brain blood vessels of uninfected and P. berghei ANKA-
infected male WT and IL-3 KO mice at day 6 p.i. Criteria used to determine what constitutes a 
damaged blood vessel can be found in the Material and Methods section. All data are presented 
as means + SEM from 6 mice per group analyzed individually. P < 0.001 (***) and P < 0.01 (**) 
versus corresponding values for uninfected mice or (as indicated by the square brackets) versus 
corresponding values for mice of the other genotype. Mice sacrificed day 6 p.i. are the same 
mice used in Figure 4 and 5. 
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uninfected controls.  Importantly, we found that infected IL-3 KO mice had a statistically 
significant decrease in the percentage of damaged vessels (~42%) as compared to corresponding 
infected WT mice (~87%) (Figure 8). However, we saw no differences between infected 
genotypes in the extent of parenchymal hemorrhaging (data not shown). Although a similar 
experiment was repeated a second time, we did not see any differences in brain histopathology 
between infected WT and IL-3 KO mice at day 7 p.i. (data not shown). Due to time restraints, 
this experiment was not repeated a third time.   
It is interesting to note that in the experiment in which we saw differences in brain 
histopathology between infected WT and IL-3 mice at day 6 p.i. (Figure 8), we also saw clear 
differences in the way these mice appeared during the course of the infection. As described in the 
Material and Methods, the clinical assessment of mice was quantified daily on a numerical scale 
of 1-5, with five representing the most severe symptoms. We found that both genotypes of mice 
did not develop clinical signs of infection until approximately 24 hours before death. At that 
time, we found that infected IL-3 KO mice experienced less severe symptoms than similarly 
infected WT mice at day 6 p.i. (numerical scores: IL-3 KO mice – 1.17; WT mice – 3.33). We 
did not see any differences in clinical symptoms in a second similar experiment in which 
infected WT and IL-3 KO mice were killed at day 7 p.i (data not shown). 
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Discussion  
IL-3 is an immunoregulatory cytokine that is primarily produced by activated T cells, but is 
also expressed by mast cells (Wodnar-Filipowicz et al., 1989) and basophils (Schroeder et al., 
2009). Studies with IL-3 KO mice have been invaluable in determining a number of key 
functions of IL-3 in vivo. For example, it has been demonstrated that IL-3 KO mice have 
impaired T cell-dependent contact hypersensitivity responses to haptens (Mach et al., 1998) and 
mount attenuated mast cell and basophil response to gastrointestinal nematode infection that 
results in compromised worm expulsion (Lantz et al., 1998). Recently, it has been observed that 
IL-3 deficiency protects mice against sepsis, and that elevated levels of IL-3 are correlated with 
increased mortality in human septic patients (Weber et al., 2015). Among the numerous IL-3 
studies conducted since its discovery in 1981 (Ihle et al., 1981), few have studied the importance 
of IL-3 in the pathophysiology of protozoan infections. Our laboratory has recently reported that 
IL-3 influences survival rates of mice infected with P. berghei NK65, as infected IL-3 KO mice 
live significantly longer than infected WT counterparts (Auclair et al., 2013). Similar to the P. 
berghei NK65 substrain, P. berghei ANKA is a lethal substrain that induces many similar 
symptoms. One marked difference, however, is that P. berghei ANKA induces cerebral malaria. 
Cerebral malaria is a primary contributor towards death in mice and is important in the 
pathogenesis of human cerebral malaria. The substrain P. berghei ANKA has yet to be studied in 
relation to IL-3, and with many similarities to P. berghei NK65, further investigation is 
necessary to determine if IL-3 is influential in the development of cerebral malaria.  
To better understand the influence of IL-3 during P. berghei ANKA infection, male and 
female IL-3 KO and WT mice were infected with 106 P. berghei ANKA pRBCs and mice were 
monitored closely for differences in survival rates. Of three male mortality experiments, one was 
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statistically significant with male IL-3 KO mice living longer than the corresponding WT mice 
(Figure 3). While the other two experiments did not depict statistical differences, the same trend 
observed in the first experiment with IL-3 KO mice living longer than their corresponding 
infected WT mice was seen. We found no significant difference in mortality between female 
infected IL-3 KO and WT mice (Figure 3C-D). Differences observed between male and female 
mice in their response to malaria infection is a common finding that may be attributed to 
immunological differences and varying sex hormones of both sexes (Klein, 2004). Furthermore, 
these mortality results using both male and female C57BL/10 mice are very similar to those 
reported using BALB/c WT and IL-3 KO mice infected with P. berghei NK65 (Auclair et al., 
2014). Additional experiments will be required to conclusively determine if IL-3 KO mice have 
prolonged survival when compared to male WT mice during a P. berghei ANKA infection. 
Plasmodium parasites utilize RBCs as both a nutrient source and host cell to replicate.  As 
the parasite infection spreads systemically, mice experience exponential RBC destruction. This 
process of replication thus makes blood parasitemia and the monitoring of hematocrit levels 
good indicators of disease severity. This is despite the fact that a significant number of P. 
berghei ANKA pRBCs sequester within blood vessels in organs such as the spleen, kidney, 
lungs, and brain (Amante et al., 2010). A higher parasitemia indicates a more severe infection, 
and a low hematocrit level indicates a high level of RBC destruction (i.e. anemia). In order to 
determine the influence of IL-3 on both blood parasitemia and hematocrit values, male IL-3 KO 
and WT mice were infected with P. berghei ANKA pRBCs and sacrificed on day 6 and 7 p.i. 
Interestingly, there was no difference observed between blood parasitemia levels for both 
genotypes at day 6 p.i. (Figure 5). No statistically significant differences were observed in 
hematocrit levels between uninfected mice and infected mice of any genotype (Figure 6). This 
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finding indicates that both WT and IL-3 KO mice are not succumbing to the infection as a result 
of high levels of anemia, but rather another cause.  
There appears to be clear differences in the results obtained by this study using P. berghei 
ANKA and those reported by Auclair et al. in which P. berghei NK65 was used to infect mice. 
These differences, however, can be explained. For example, this study infected mice with a ten-
fold greater dose of pRBCs. While the same trend in survival rates between P. berghei NK65 and 
P. berghei ANKA was observed, the ten-fold increase in injected P. berghei ANKA pRBCs 
could have accounted for there not being a marked difference between the genotypes. In addition 
to parasite strain differences, different strains of inbred mice were used by each study.  There are 
known differences in the physiology and immune systems of C57BL/10 versus BALB/c mice 
and these differences likely influence not only mortality but also the degree of parasitemia. It is 
important to also note that statistically significant differences in parasitemia that was observed in 
P. berghei NK65-infected BALB/c mice were not seen until day 8 p.i. (Auclair et al., 2014). In 
this study, P. berghei ANKA-infected C57BL/10 mice often die by day 6 p.i., and so parasitemia 
was evaluated very early during infection. At this early time point, sufficient levels of IL-3 may 
not yet be produced to influence the infection. Furthermore, our results suggest that the early 
death seen in both genotypes is likely not due to anemia or high levels of parasitemia but instead 
is caused by neurological damage induced by sequestered pRBCs and leukocytes in the brain. 
Splenomegaly, or enlargement of the spleen, is commonly seen in both humans and in mice 
infected with Plasmodium parasites. As stated above, the Plasmodium parasite utilizes RBCs as a 
nutrient source, and ultimately causes them to rupture. The spleen has several functions. It is a 
major secondary lymphoid organ, and it functions in the clearance of damaged RBCs. In the 
splenic red pulp, regulatory cells such as macrophages and dendritic cells work to remove 
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parasitized or damaged RBCs (Ing et al, 2006). Simultaneously in the splenic white pulp, 
Plasmodium-specific immune cells such as lymphocytes undergo exponential proliferation in an 
attempt to control the infection (Mizobuchi et al., 2014). The combination of these functions 
contribute to an enlargement of the spleen. 
To determine if IL-3 influences the splenomegaly during a P. berghei ANKA infection, male 
IL-3 KO and WT mice were infected and the splenic index was calculated at day 7 p.i. 
Uninfected mice of both genotypes were used as controls. Interestingly, not only did both 
genotypes of mice exhibit an increase in the splenic index as compared to control mice, but 
infected IL-3 KO mice had a significantly larger increase in spleen size (~70% greater) 
compared to infected WT mice (Figure 4).  This finding is particularly important, as 
splenomegaly is a common clinical manifestation found in humans infected with P. falciparum 
(Buffet et al., 2011). A greater splenomegaly in IL-3 KO mice was also noted in BALB/c mice 
infected with P. berghei NK65 (Auclair et al., 2014). A significantly larger splenomegaly in IL-3 
KO mice could indicate that the spleen of these mice may be mounting a more robust immune 
response to infection and/or that they are more efficient at sequestering and clearing pRBCs. 
Both of these events would lead to an increase in spleen size. 
Cerebral malaria is the most severe clinical manifestation in humans infected with P. 
falciparum and in mice infected with P. berghei ANKA. Cerebral malaria is characterized by 
extensive pRBC and leukocyte sequestration in the brain microvasculature that in some cases 
leads to parenchymal hemorrhaging. Associated neurological complications range from minor 
head tilts to total body paralysis and death. Previous, non-malaria studies have demonstrated that 
IL-3 is produced in the brain and that IL-3 influences brain physiology (Kronfol and Remick, 
2000). For example, IL-3 has been observed as a neurotropic factor for murine central 
	40	
cholinergic neurons (Konishi et al. 1994). Interestingly, overexpression of IL-3 in transgenic 
mice has also been linked with motor neuron disease (Chavany et al., 1998), further indicating an 
important role of IL-3 in brain function.  
In order to determine if IL-3 has any effect on the development of cerebral malaria, IL-3 KO 
and WT mice were injected with P. berghei ANKA and coronal brain sections examined at days 
6 and 7 p.i. While both genotypes developed cerebral malaria, in one experiment, WT mice 
displayed more extensive vessel damage than the infected IL-3 KO (Figure 8). This difference 
indicates that IL-3 may play a role in suppressing immunity against infection. This finding also 
correlates with our observation of an increased trend in survival rate among infected male IL-3 
KO mice. In addition to evident differences in brain histopathology, infected IL-3 KO mice also 
appeared healthier in the one experiment in which we observed differences in brain histology. 
Unfortunately, these results were not seen in a second experiment in which mice were infected 
and killed day 7 p.i. 
Future studies will be required to conclusively determine if IL-3 influences survival and the 
severity of cerebral malaria in this mouse model of infection. One possible change to consider in 
performing future experiments would be to lower the number of pRBCs used to infect mice. 
Mice do not constitutively produce IL-3 under baseline conditions (Mach et al., 1998).  Thus, 
lowering the dosage of pRBCs used to infect mice may allow mice to live longer and be able to 
produce significantly greater amounts of IL-3 that could influence the infection. In this situation 
for example, differences in survival and brain histopathology between IL-3 KO and WT mice 
may be more distinct.  
In conclusion, we have observed that IL-3 influences certain clinical outcomes in a mouse 
model of cerebral malaria in which C57BL/10 mice are infected with P. berghei ANKA. We 
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observed major differences attributed to IL-3 in the spleen and brain. These differences suggest 
that IL-3 plays a role in suppressing protective immunity to P. berghei ANKA infection.  While 
many of the results parallel those found by those studies which used P. berghei NK65 (Auclair et 
al., 2014), there are some key differences. Differences that exist regarding the outcome seen in 
mice infected with either P. berghei ANKA and P. berghei NK65 are likely due to differences 
between the malaria parasite and the particular inbred mouse strain utilized in experiments. 
Regardless of the particular parasite used, it will be important in future studies to determine the 
source of IL-3 during an infection and to determine the cellular targets for IL-3 once it has been 
produced. In conjunction with more extensive brain histopathological analysis, further studies 
will help to elucidate the mechanism by which IL-3 influences the development of cerebral 
malaria. Ultimately, we believe our studies presented here, along with those reported by Auclair 
et al. using P. berghei NK65, will aid in understanding the contributions of IL-3 in the resistance 
of mice to blood-stage malaria infection.   
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